EVP Linda Burkly of Editas (NASDAQ: EDIT) logs automatic tax-related share sale

Rhea-AI Filing Summary

Editas Medicine, Inc. executive Linda Burkly, EVP and Chief Scientific Officer, reported an open-market sale of 749 shares of common stock at a weighted average price of $2.0196 per share. After this transaction, she held 68,028 shares of Editas Medicine common stock.

According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 3, 2023 and was made to cover tax withholding obligations from restricted stock units that vested on March 2, 2026. The filing states that this was not a discretionary trade by the reporting person.

Insider Trade Summary

Net Seller: 749 shares ($1,513)

Net Sell 1 txn

Insider Burkly Linda

Role EVP, CHIEF SCIENTIFIC OFFICER

Sold 749 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	749	$2.0196	$2K

Holdings After Transaction: Common Stock — 68,028 shares (Direct)

Footnotes (1)

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.0041 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burkly Linda

(Last) (First) (Middle)

11 HURLEY ST.

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		749	D	$2.0196(2)	68,028	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

2. This transaction was executed in multiple trades at prices ranging from $2.0041 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected

Remarks:

	/s/ Linda C. Burkly	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Editas Medicine (EDIT) report for Linda Burkly?

Editas Medicine reported that EVP and Chief Scientific Officer Linda Burkly sold 749 shares of common stock. The transaction was an open-market sale at a weighted average price of $2.0196 per share, leaving her with 68,028 Editas Medicine shares afterward.

Was the Linda Burkly Editas Medicine (EDIT) stock sale a discretionary trade?

The sale was not discretionary. It was executed under a durable automatic sales instruction plan adopted on July 3, 2023, and was made solely to satisfy tax withholding obligations arising from restricted stock units that vested on March 2, 2026.

How many Editas Medicine (EDIT) shares does Linda Burkly hold after the reported sale?

After selling 749 shares, Linda Burkly beneficially owned 68,028 shares of Editas Medicine common stock. This figure reflects her holdings following the tax-related sale disclosed in the Form 4 insider transaction report.

At what price did Linda Burkly’s Editas Medicine (EDIT) stock sale occur?

The reported sale used a weighted average price of $2.0196 per share. The transaction occurred in multiple trades executed between $2.0041 and $2.0204, as disclosed in the footnotes accompanying the insider trading report.

Why did Linda Burkly sell Editas Medicine (EDIT) shares according to the filing?

The filing states the shares were sold to meet tax withholding obligations from restricted stock units that vested on March 2, 2026. The trades were executed under a pre-established automatic sales instruction plan, not as a discretionary investment decision.